In: Scientific Reports, 2020, vol. 10, no. 1, p. 7078
Immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), have resulted in unprecedented improvements in survival for patients with lung cancer. Nonetheless, not all patients benefit equally and many issues remain unresolved, including the mechanisms of action and the possible effector function of immune cells from non-lymphoid lineages. The purpose of this...
|
In: Virchows Archiv, 2014, vol. 464, no. 3, p. 359-365
|
In: World Journal of Surgery, 2012, vol. 36, no. 2, p. 386-391
|
In: European Journal of Nuclear Medicine and Molecular Imaging, 2005, vol. 32, no. 6, p. 641-646
|
In: Supportive Care in Cancer, 2012, vol. 20, no. 1, p. 141-147
|
In: Journal of Nuclear Cardiology, 2004, vol. 11, no. 3, p. 361-363
|
In: Cancer Causes & Control, 2009, vol. 20, no. 9, p. 1689-1696
|
In: Clinical and Translational Oncology, 2009, vol. 11, no. 5, p. 312-317
|
In: Clinical and Translational Oncology, 2012, vol. 14, no. 5, p. 321-322
|
In: European Journal of Nuclear Medicine and Molecular Imaging, 2012, vol. 39, no. 6, p. 936-943
|